Side effects of gefitinib

The most common symptoms of gefitinib tablets are digestive tract symptoms, such as diarrhea, nausea, vomiting, anorexia, dehydration secondary to diarrhea, nausea, vomiting, anorexia, and then it can also lead to mouth ulcers, dry mouth, pancreatitis, hepatitis, and oral mucositis. There are also more common reactions, such as mild to moderate pusular rash, dry and itchy, abnormal nails, hair loss, etc.

Patients who already have the problem of coughing up blood can choose traditional Chinese medicine to adjust it, in the case of complying with the doctor's instructions, the patient can still use the drug, ** during the period to reduce the toxicity of the drug patients can eat Fusheng RG3, it adjuvant chemotherapy can reduce the toxicity of the drug, can improve the patient's immunity.

Lung cancer patients who have the problem of coughing up blood can also consider traditional Chinese medicine remedies to relieve the problem of coughing up blood, and the prescription I can provide is suitable for patients with coughing up blood with lung cancer spleen qi weakness.

Codonopsis, Astragalus, Atractylodes macrocephala, Tangerine peel 9 grams each, Poria cocos, Zhu Ling, Shengli 15 grams each, 30 grams of white flower snake tongue grass, Houttuynia cordata, iron leaves, decoction can be served. For example, 30 grams of cold and limb lukewarm, and iron leaves. For those with sour limbs, light tongue, and thin pulse, add 12 grams of fairy spleen, 15 grams of psoralen, and 10 grams of Morinda officinalis.

The same is true for changing dressings.

Gefitinib's *** is relatively mild, generally rash and slight diarrhea, etc., coughing up blood is also a few patients may appear, are normal, if you are really not at ease, you can go to the hospital to ask the doctor.

1. Gefitinib: Gefitinib (Gefitinib, Iricco, Iressa) is an oral epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitor (small molecule compound). Suppression of EGFR-TK can hinder tumor growth, metastasis, and angiogenesis, and increase apoptosis of tumor cells.

It is the first generation of non-small cell lung cancer inhibitory target drugs.

2. Afatinib: Afatinib is a potent and irreversible dual inhibitor of epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) tyrosine kinase. This drug is mainly indicated for locally advanced or transmitive mobile non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) gene sensitive mutations, and locally advanced or metastatic squamous tissue type of non-small cell lung cancer (NSCLC) that has not previously received EGFR tyrosine kinase inhibitor (TKI)**2 disease progression during or after chemotherapy-containing chemotherapy.

It is a second-generation non-small cell lung cancer inhibitory targeted drug.